Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website - Seite 2

Many respondents felt unprepared for physical side effects. While 54% of individuals experienced diarrhea or fecal incontinence as a treatment side effect, 22% of affected individuals did not feel informed about the possibility of such side effects. Survey findings also highlight the consequences of treatments to manage side effects. Thirty-seven percent of respondents were prescribed treatment to address diarrhea and 100% of these patients reported additional side effects stemming from this supportive care, including nausea, constipation, and fatigue.

"A significant number of the abstracts submitted to SABCS 2023 refer to cancer therapies with ‘manageable toxicities' and ‘tolerable side effects,'" said Lisa Conte, Jaguar's president and CEO. "We acknowledge the rigors of both short-term and perpetual treatment and do not believe any cancer therapy-related side effect, whether it is extreme fatigue, debilitating diarrhea, chronic pain, or others, should ever be viewed as ‘tolerable' or ‘manageable.' When clinical studies refer to manageable toxicities, patients ask, ‘manageable for whom?'"

Advocates for Collaborative Education, a global coalition of patient, community, research, and policy advocates, initiated an anonymous, online survey to assess Quality of Life (QoL) impacts of cancer diagnosis and treatment to inform research, clinical care, and the broader cancer community. Identifying what matters most to individuals can potentially guide improvements in supportive care to effectively address QoL impacts.

Jaguar's poster outlining the design of the company's pivotal Phase 3 OnTarget trial for cancer therapy-related diarrhea (CTD) and the neglected medical need of CTD will also be presented at SABCS on December 7^th. The trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The top line results of the study are forthcoming.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.